Jump to content

User:Mr. Ibrahem/Oxamniquine

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Oxamniquine
Clinical data
Trade namesVansil
AHFS/Drugs.comMicromedex Detailed Consumer Information
Routes of
administration		by mouth
Legal status
Legal status
  • US: Not commercially available
Pharmacokinetic data
BioavailabilityReadily absorbed when taken by mouth
Metabolismliver
Elimination half-life1 to 2.5h
Excretionmainly in urine
Identifiers
  • (RS)-1,2,3,4-Tetrahydro-2-isopropylaminomethyl-7-nitro-6-quinolylmethanol
Chemical and physical data
FormulaC14H21N3O3
Molar mass279.3 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • [O-][N+](=O)c1c(cc2c(c1)NC(CC2)CNC(C)C)CO
  • InChI=1S/C14H21N3O3/c1-9(2)15-7-12-4-3-10-5-11(8-18)14(17(19)20)6-13(10)16-12/h5-6,9,12,15-16,18H,3-4,7-8H2,1-2H3 checkY
  • Key:XCGYUJZMCCFSRP-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Oxamniquine, sold under the brand name Vansil among others, is a medication used to treat schistosomiasis due to Schistosoma mansoni.[2] Praziquantel, however, is often the preferred treatment.[3] It is given by mouth and used as a single dose.[3]

Common side effects include sleepiness, headache, nausea, diarrhea, and reddish urine.[2] It is typically not recommended during pregnancy, if possible.[2] Seizures may occur and therefore caution is recommended in people with epilepsy.[2] It works by causing paralysis of the parasitic worms.[4] It is in the anthelmintic family of medications.[5]

Oxamniquine was first used medically in 1972.[6] It is on the World Health Organization's List of Essential Medicines.[7] It is not commercially available in the United States.[5] It is more expensive than praziquantel.[8]

References[edit]

  1. ^ Cite error: The named reference who was invoked but never defined (see the help page).
  2. ^ a b c d World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 94. hdl:10665/44053. ISBN 9789241547659.
  3. ^ a b Griffiths, Jeffrey; Maguire, James H.; Heggenhougen, Kristian; Quah, Stella R. (2010). Public Health and Infectious Diseases. Elsevier. p. 351. ISBN 9780123815071. Archived from the original on 2016-12-20.
  4. ^ Cohen, Jonathan; Powderly, William G.; Opal, Steven M. (2016). Infectious Diseases (4 ed.). Elsevier Health Sciences. p. 1371. ISBN 9780702063381. Archived from the original on 2016-12-20.
  5. ^ a b "Oxamniquine medical facts from Drugs.com". www.drugs.com. Archived from the original on 20 December 2016. Retrieved 10 December 2016.
  6. ^ Jordan, Peter (1985). Schistosomiasis: The St Lucia Project. CUP Archive. p. 298. ISBN 9780521303125. Archived from the original on 2017-09-10.
  7. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  8. ^ "International Strategies for Tropical Disease Treatments - Experiences with Praziquantel - EDM Research Series No. 026: Chapter 2: Bayer & E. Merck: Discovery and development of praziquantel*: Competing drugs for schistosomiasis treatment". apps.who.int. Archived from the original on 20 December 2016. Retrieved 10 December 2016.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Oxamniquine&oldid=1233784855"